Ligand validation:6ZLK

UGB: (2S,3R,4S,5R,6R)-6-[[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-3,4,5-trihydroxy-oxane-2-carboxylic acid

UGB is a Ligand Of Interest in 6ZLK designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6ZLK_UGB_D_403	95%	61%	0.074	0.977	0.67	0.81	1	1	2	0	100%	0.5
6ZLK_UGB_A_403	90%	59%	0.087	0.971	0.65	0.9	1	3	3	0	100%	0.5081
6ZLK_UGB_C_403	90%	61%	0.084	0.967	0.64	0.83	1	2	2	0	100%	0.5081
6ZLK_UGB_B_403	89%	61%	0.088	0.968	0.75	0.74	1	-	3	0	100%	0.5081
6ZLL_UGB_A_401	92%	54%	0.081	0.972	0.74	1.03	1	2	3	0	100%	0.9946
3OH1_UGB_A_642	60%	9%	0.143	0.929	1.83	2.6	8	18	2	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.